Expert Insights

John Strickler, MD, discusses results from the primary analysis of the phase 2 MOUNTAINEER trial, which demonstrated clinically meaningful antitumor activity with tucatinib plus trastuzumab for patients with HER2-positive metastatic...

Alessandra Raimondi, MD, discusses results from an individual patient data pooled analysis of the Valentino and Panama clinical trials exploring the optimal maintenance treatment strategy following anti-EGFR-based induction therapy for...

Mohamed Salem, MD, discusses findings from a study exploring the impact of a BRAF V600E mutation on immunologic characteristics of the tumor microenvironment and associated genomic alterations in microsatellite instability (MSI)-high or...

Anthony El-Khoueiry, MD, discusses results from an analysis of patients with microsatellite stable colorectal cancer treated with botensilimab plus balstilimab in an expanded phase 1a/b study.

Yelena Janjigian, MD, discusses findings from a preliminary biomarker analysis of the ongoing DESTINY-Gastric03 trial, which explored concordance between local and central HER2 testing and overlap of PD-L1 and HER2 expression in gastric...

Andrea Casadei-Gardini, MD, discusses findings from an international study examining atezolizumab plus bevacizumab vs lenvatinib or sorafenib in patients with non-viral unresectable hepatocellular carcinoma.

Firas Baidoun, MD, discusses findings from a study that compared survival outcomes between upfront liver transplant, liver transplant with bridge systemic therapy, and systemic therapy only, for non-metastatic hepatocellular carcinoma.

Matthieu Faron, MD, discusses findings from an individual participant data network meta-analysis which identified the best neoadjuvant treatment for patients with esophageal or GEJ carcinoma across prespecified subgroups.

Kevin Kalinsky, MD, discusses findings from a phase 2 study exploring the efficacy of fulvestrant or exemestane with or without ribociclib in patients with HR-positive, HER2-negative metastatic breast cancer after progression on CDK 4/6...

Anthony Mato, MD, PhD, highlights findings from a post-hoc analysis of the phase 3 MURANO trial, which explored the impact of venetoclax dose modification and early discontinuation on survival outcomes for patients with CLL.